Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Adv Ther · 2017 · PMC5702366 · PMID 29094315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

[ 17 ] also reported a statistically significant increase in trough FEV 1 with UMEC/VI compared with twice-daily administration of aclidinium/formoterol, as well as a nonsignificant trend favoring UMEC/VI over TIO/OLO.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.